Neurology

Latest News
September 8th 2025

Treatment Challenges, Options for People With MS and Comorbid Inflammatory Diseases

August 29th 2025

Long-Term Data Reinforce Givinostat Efficacy, Safety in DMD

August 26th 2025

Identifying Signs of Presymptomatic MS, Radiologically Isolated Syndrome

August 25th 2025

Genetic Burden of Depression Linked to Increased MS Disease Activity and Disability

August 13th 2025

DYNE-251 Granted FDA Breakthrough Therapy Designation for DMD

Video Interviews
View All
April 2nd 2025

The Value of Newborn Screening for DMD: Barry Byrne, MD, PhD

October 23rd 2024

Future Considerations for Friedreich Ataxia

October 16th 2024

Comorbidities and Complications Associated With Friedreich Ataxia

October 16th 2024

Challenges Associated With Friedreich Ataxia

October 9th 2024

Impact of Friedreich Ataxia on Quality of Life

October 9th 2024

Clinical Utility of the Modified Friedreich Ataxia Rating Scale

October 2nd 2024

Diagnosis of Friedreich Ataxia

October 2nd 2024

Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

September 11th 2024

Friedreich Ataxia: Looking Forward at the Treatment Landscape

June 26th 2024

Concluding Remarks: Impact of Alzheimer Disease, Promising Treatments in Development, and Future Outlook

More News

Following an investigation, the FDA confirmed that shipments of delandistrogene moxeparvovec can resume. | Image Credit: immimagery - stock.adobe.com
July 31st 2025

FDA Recommends Sarepta Resume DMD Gene Therapy Shipments for Ambulatory Patients

Rose McNulty
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a voluntary pause.
cognition and alzheimer's disease/dementia | Image credit: Orawan - stock.adobe.com
July 30th 2025

Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias

Skylar Jeremias
Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.
kid with MS and doctor | Image credit: Halfpoint - stock.adobe.com
July 30th 2025

Emerging Strategies to Manage Pediatric-Onset Multiple Sclerosis

Skylar Jeremias
Discover the latest insights on pediatric-onset multiple sclerosis, emphasizing early intervention and high-efficacy therapies for improved outcomes in children.
The authors reported robust correlations between composite mean greyscale values and key functional outcomes in DMD. | Image Credit: hafakot - stock.adobe.com
July 29th 2025

Quantitative Muscle Ultrasound a Promising Noninvasive Biomarker for DMD

Kimberly Rath, PharmD
Quantitative muscle ultrasound correlates strongly with ambulatory and timed function tests in Duchenne muscular dystrophy, suggesting it could complement or even replace more burdensome assessments.
Older woman using nose spray | Image credit: Yuliia – stock.adobe.com
July 23rd 2025

Insulin Nasal Spray Reaches Memory Centers in Brain, Offering Hope for Alzheimer Treatment

Hayden E. Klein
The 16-person, first-in-human study showed promising safety and efficacy data for delivering insulin intranasally in older adults.
MS ribbon and brain drawing | Image credit: Pixel-Shot - stock.adobe.com
July 16th 2025

Review Highlights Gaps in Transition From Pediatric to Adult MS Care

Skylar Jeremias
Pediatric patients with multiple sclerosis (MS) face significant challenges transitioning to adult care, risking treatment delays and long-term health outcomes.
The primary outcome measure in the ambulatory cohort in the study was mean change from baseline to week 52 in the TTR from floor, and no significant differences were seen between the treatment and control groups. | Image credit: OlegKachura - stock.adobe.com
July 11th 2025

TAS-205 Misses Primary End Point in Phase 3 DMD Trial

Rose McNulty
TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.
While accommodations can improve quality of life for patients with DMD and foster independence, the costs of home and ve modifications fall mostly on the families of patients. | Image credit: Nadzeya - stock.adobe.com
July 10th 2025

Accommodations as DMD Progresses Incur Substantial Household Costs

Rose McNulty
Families caring for individuals with Duchenne muscular dystrophy (DMD) face significant financial burdens from necessary home and vehicle modifications to enhance quality of life.
An analysis of outcomes from part 2 of the EMBARK trial included 14 patients who had received a placebo in part 1 of the study and were aged 8 to 9 years at crossover. | Image Credit: RFBSIP - stock.adobe.com
June 13th 2025

DMD Gene Therapy Shows Clinical Benefits in 8- and 9-Year-Old Patients

Rose McNulty
The findings support the clinical benefits of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD).
Alzheimer disease. | Image Credit: ipopba - stock.adobe.com
June 5th 2025

Alzheimer Disease and Related Dementias Cause Surging Economic Burden for Minoritized Communities

Cameron Santoro
African American and Latino older adults with Alzheimer disease and related dementias and their families are likely to face disproportionately high burdens, primarily associated with unpaid caregiving, suggesting the need for policies that may reduce economic burdens for all US residents.
While significant progress has been made, innovations in vector design, immune modulation, and delivery strategies are needed to further improve gene therapy for DMD. | Image credit: RFBSIP - stock.adobe.com
May 30th 2025

Hurdles Remain Despite Progress in Gene Therapy for DMD

Rose McNulty
Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.
Women in science | Image Credit: © metamorworks-stock.adobe.com.jpeg
May 23rd 2025

5 Rare Disorders Named for Pioneering Female Scientists

Maggie L. Shaw
Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.
FDA Approved. | Image Credit: Pixelcrafts - stock.adobe.com
May 19th 2025

FDA Clears First Blood Test for Early Detection of Alzheimer-Linked Amyloid Plaques

Cameron Santoro
The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.
Quantitative magnetic resonance imaging seemed to show that delandistrogene moxeparvovec protects muscle from progressive damage in DMD. | Image credit: OlegKachura - stock.adobe.com
May 14th 2025

Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression

Rose McNulty
Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
While previous research on the DVA focused on task-specific measurements, the new study focused on total composite severity percentage among patients with DMD. | Image credit: ChiccoDodiFC - stock.adobe.com
April 18th 2025

At-Home DMD Video Assessment Found Valid, Reliable

Rose McNulty
The remote measurement tool enables Duchenne muscular dystrophy (DMD) assessments through analysis of caregiver-recorded videos.
Kavita Nair Q&A - Maks_Lab - stock.adobe.com.jpeg
March 12th 2025

Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

Christina Mattina Kavita V. Nair, PhD
In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.
FDA | Image credit: Postmodern Studio
February 26th 2025

Adaptive Deep Brain Stimulation Technology Receives FDA Approval for Parkinson Disease

Giuliana Grossi
The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease.
Vertebral fractures are common in glucocorticoid-associated osteoporosis and are a clinical indicator of osteoporosis in young patients. | Image credit: Hugnaka - stock.adobe.com
February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty
Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).
Parkinson disease | Image credit: wladimir1804 - stock.adobe.com
February 4th 2025

FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease

Skylar Jeremias
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease.
Stroke. | Image Credit: Chinnapong - stock.adobe.com
January 30th 2025

New Model Predicts Stroke Severity and Improves Functional Independence

Cameron Santoro
A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining functional independence.
Duchenne muscular dystrophy | Image credit: hafakot - stock.adobe.com
January 28th 2025

EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD

Rose McNulty
The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years in patients with Duchenne muscular dystrophy (DMD).
FDA headquarters | Image Credit: Grandbrothers - stock.adobe.com
January 27th 2025

FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease

Brooke McCormick
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Heart and stethoscope | Image credit: inthasone - stock.adobe.com
January 24th 2025

Prophylactic Cardiac Medication May Prolong Survival in DMD

Rose McNulty
Prophylactic cardiac treatment may prolong survival in Duchenne muscular dystrophy (DMD), but only one-quarter of individuals received such treatment, a recent study found.
Past studies have explored the association between motor and cardiac function in younger patients with DMD, but there is a lack of research on this relationship as patients with DMD age. | Image credit: Nana_studio - stock.adobe.com
January 13th 2025

Later Loss of Ambulation Linked With Better Heart Health in DMD

Rose McNulty
The results suggest that prolonging ambulation may not adversely impact cardiac function in adulthood for patients with Duchenne muscular dystrophy (DMD).
Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
January 6th 2025

Pain May Be Indicator of MS Prior to Disease Onset: Study

AJMC Contributor
Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.
Better understanding the vascular sequelae of MS may similarly unlock predictive insights for people with MS, according to investigators. | Image credit: Elena - stock.adobe.com
January 3rd 2025

Meta-Analysis: Vascular Function Worse in People With MS

Jared Kaltwasser
The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.
lab test tubes | Image credit: kwanchaift – stock.adobe.com
December 22nd 2024

Study Highlights Trends, Emerging Innovations in DMD Research

Hayden E. Klein
An analysis revealed global trends and emerging focus areas in Duchenne muscular dystrophy (DMD) research, emphasizing the growing impact of precision medicine and gene therapies.
Nurse helping patient use walker | Image credit: LIGHTFIELD STUDIOS – stock.adobe.com
October 9th 2024

Genotypes May Influence When Patients With DMD Have Loss of Ambulation

Hayden E. Klein
A study of 555 patients further solidified genotype-phenotype correlations in Duchenne muscular dystrophy (DMD).
Currently, 4 exon-skipping drugs are FDA approved for DMD: eteplirsen (Exondys 51), golodirsen (Vyondys 53), casimersen (Amondys 45), and viltolarsen (Viltepso) | Image credit: CrazyJuke - stock.adobe.com
September 26th 2024

WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis

Rose McNulty
In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
The new results make HERCULES the first and only study to demonstrate reduced CDP in nrSPMS. | Image credit: Juan Gärtner - stock-adobe.com
September 3rd 2024

Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS

Rose McNulty
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).
12>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo